The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Open accessAbstract
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All these effects are consistent with reported roles of APOE4 in inflammation, synaptic impairment, MAPK1 signaling and downstream APP transcription, and early endosomes7,18.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is associated with increased amyloid-β deposition, hyperphosphorylation and aggregation of tau, and accelerated cognitive decline4–7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE4 polymorphism alters the accessibility of the lipid-binding region, which interferes with its cholesterol and lipid transport capacity7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“having the APOE ɛ4 coding mutation(s) increases AD risk 3–15 fold [3]”
From Association of SPI1 haplotypes with altered SPI1 gene expression and Alzheimer’s disease risk (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include PLCG2 P522R rare variant (rs72824905) that provides robust protection against AD (odds ratio ≈ 0.68 [1, 4], comparable to having one APOE2 allele [5]”
From PLCγ2 deficiency compromises systemic immune tolerance and erodes myelin homeostasis while enhancing oxidative metabolism in the mouse brain (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE is the most important risk factor for AD and contributes significantly to the risk of developing several other neurological and nonneurological disorders (18).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the APOE-E4 allele confers a ∼ 3.7 times greater risk than the common variant, APOE-E3, whereas homozygous APOE-E4/E4 carriers have a ∼12-15 times greater risk for developing AD.”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE genotype is the strongest genetic risk factor for AD21, with APOE ε2 conferring protection from disease and APOE ε4 conferring higher risk, compared to the APOE ε3 allele”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, binding to LDLR is required by ApoE to perform its downstream effector function (50–52).”
From Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis (2024) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies have consistently implicated immune-related pathways in AD susceptibility, particularly those involving microglial function [21,22].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When activated, microglia, the resident immune cells of the central nervous system, play a central role in amyloid clearance, synaptic remodeling, and the regulation of inflammatory signaling within the brain [21].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE gene is a known genetic risk factor for neurodegeneration and cardiovascular disease (CVD) [1, 2].”
From Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 exacerbates amyloid pathology by promoting Aβ production and aggregation, and inhibiting Aβ clearance and degradation”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 aggravates the tau pathology via promoting tau phosphorylation, aggregation, propagation, and tau-mediated neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 mediates and regulates the endocytosis of > 30 ligands, including apolipoprotein E (APOE) and amyloid-β (Aβ) [21–27]”
From LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Compared with APOE3, the APOE4 isoform increases AD risk and theAPOE2 isoform reduces AD risk.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 isoform may affects the development and progression of AD through multiple different pathways in which inflammatory regulation plays crucial role.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that APOE is predominantly expressed in glial cells, particularly astrocytes and activated microglia, which play central roles in A β accumulation, clearance, and neuroin fl ammation 3,4 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Hyperphosphorylated forms of the microtubule-associated protein tau in neurons is a major hallmark of AD [2, 3].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple cohort studies have demonstrated that the APOE ε4 allele is a major genetic risk factor for AD”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“while the three common isoforms (APOE2, APOE3, and APOE4) influence both amyloid‐β–dependent and independent pathways implicated in AD pathogenesis [1, 2].”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“APOE plays a crucial role in the pathophysiology of AD, particularly in relation to Aβ and tau.43,44”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Cerebrovascular dysfunction has been recognized as a major pathological process of AD”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
The cited source says what the claim attributes to it.
In the citing paper
“with ApoE4-positive cells showing reduced function (Rawat et al., 2019; Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“ApoE4 shows both loss-of-function and gain-of-toxic-function across various AD pathogenesis pathways (Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, cerebral glucose hypometabolism occurs in both the early stage of AD (Christian et al., 2020; Yamazaki et al., 2019) and epilepsy (McDonald et al., 2018; Patel, 2018).”
From APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice (2026) · cites this paper as Yamazaki et al., 2019
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“We also found that LECs isolated from the meninges of 6-month-old 5xFAD mice showed significant changes in the expression of genes involved in processes such as exocytosis, phospholipase D signaling, and response to low-density lipoprotein (Extended Data Fig. 1f–k), suggesting that meningeal Aβ deposition might affect meningeal LECs early on through deleterious processes previously implicated in”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a specific ApoE4 fragment, ApoE4[Δ(166-299)], has previously been found to promote the cellular uptake of extracellular Aβ42 and resulted in increased oxidative stress [28], similar to the effect of L28P.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“APOE is the most significant known risk factor for sporadic Alzheimer’s disease”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“ApoE4 exhibits the strongest receptor binding and is considered a high-risk allele, while ApoE2 exhibits the weakest receptor binding and is considered protective (Yamazaki et al., 2019).”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“APOE also affects tau pathogenesis and tau-mediated neurodegeneration [468].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [468]
In the citing paper
“In fact, 39 AD-associated genes were found within the 10th percentile of highly expressed genes in meningeal LECs, including Apoe, which is intrinsically linked to altered risk for late onset AD15,31 and was one of the few highly expressed genes found at the intersection between all three cell types (Extended Data Fig. 9o).”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Self-citation
Cited by
Sorted by citations
Items 601–700 of 1,006
Homeostasis of Lipid Metabolism in Disorders of the Brain
Johnson, J. L., & Johnson, L. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00146-8 · Cited by 13
Potential therapeutic natural compounds for the treatment of Alzheimer's disease
Huang, Q., Wu, W., Wen, Y., Lu, S., & Zhao, C. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155822 · Cited by 12
Exploring the effect of APOE ε4 on biomarkers of neurodegeneration in Alzheimer’s disease
Agnello, L., Gambino, C. M., Ciaccio, A. M., Piccoli, T., Blandino, V., Scazzone, C., Sasso, B. L., Ben, F. D., & Ciaccio, M. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119876 · Cited by 12
Zillich, E., Belschner, H., Avetyan, D., Andrade-Brito, D., Martínez‐Magaña, J. J., Frank, J., Mechawar, N., Turecki, G., Cabana‐Domínguez, J., Fernàndez‐Castillo, N., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03139-9 · Cited by 12
Asokan, K., Sivaraman, S., Nallasamy, K., Jeyavijayan, S., & Paranthaman, S. (2024) · International Journal of Quantum Chemistry · doi:10.1002/qua.70006 · Cited by 12
Wang, F., Wang, J., Luo, N., Luo, Y., Gao, Z., Ye, C., Jiang, M., Shen, Z., Xiao, J., Xue, P., et al. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.117736 · Cited by 13
Yang, X., Yao, K., Zhang, M., Zhang, W., & Zu, H. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111321 · Cited by 12
Zhao, Q., Xu, J., Shi, Z., Zhang, Y., Du, X., Zhai, Y., Xu, J., Liu, F., & Zhang, Q. (2025) · Research · doi:10.34133/research.0688 · Cited by 12
Accelerated midlife endocrine and bioenergetic brain aging in APOE4 females
Wang, T., Mao, Z., Shang, Y., Merlini, S., Vitali, F., Wiegand, J. L., & Brinton, R. D. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1632877 · Cited by 12
Effective in vivo RNA base editing via engineered cytidine deaminase APOBECs fused with PUF proteins
Han, W., Yuan, B., Fan, X., Li, W., Yuan, Y., Zhang, Y., Wang, S., Shan, S., Hafner, M., Wang, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64748-6 · Cited by 12
Modeling neurodegenerative diseases with brain organoids: from development to disease applications
Larriba-González, T., García-Martín, M., Ojeda-Hernández, D. D., Rincón-Cerrada, P., Martín-Blanco, L., Benito‐Martín, M. S., Selma-Calvo, B., de la Fuente-Martín, S., Matías‐Guiu, J. A., Matías‐Guiu, J., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1663286 · Cited by 12
Beretti, F., Malenchini, M., Gatti, M., & Maraldi, T. (2025) · Biomedicines · doi:10.3390/biomedicines14010059 · Cited by 12
Wang, L., Jiao, Y., Zhao, A., Xu, X., Ye, G., Zhang, Y., Wang, Y., Deng, Y., Xu, W. L., & Liu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.819499 · Cited by 12
Using Polygenic Hazard Scores to Predict Age at Onset of Alzheimer’s Disease in Nordic Populations
Motazedi, E., Cheng, W., Thomassen, J. Q., Frei, O., Rongve, A., Athanasiu, L., Bahrami, S., Shadrin, A. A., Ulstein, I. D., Stordal, E., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220174 · Cited by 12
Santos‐Sánchez, G., Ponce‐España, E., López, J. C., Álvarez‐Sánchez, N., Álvarez‐López, A. I., Pedroche, J., Millán, F., Millán-Linares, M. C., Lardone, P. J., Bejarano, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179828 · Cited by 12
Sapkota, S., Erickson, K., Fletcher, E. M., Farias, S. T., Jin, L., DeCarli, C. S., & Initiative, A. D. N. (2023) · Stroke · doi:10.1161/strokeaha.122.041854 · Cited by 12
Alzheimer’s disease cortical morphological phenotypes are associated with TOMM40′523-APOE haplotypes
Honea, R. A., Hunt, S. L., Lepping, R. J., Vidoni, E. D., Morris, J. K., Watts, A. S., Michaelis, E. K., Burns, J. M., & Swerdlow, R. H. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.09.001 · Cited by 12
Shaik, S. M., Cao, Y., Gogola, J. V., Dodiya, H. B., Zhang, X., Boutej, H., Han, W., Križ, J., & Sisodia, S. S. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00668-7 · Cited by 12
Cho, S. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042211 · Cited by 12
Mamma Mia, P‐glycoprotein binds again
Callaghan, R., Gelissen, I. C., George, A. M., & Hartz, A. M. S. (2020) · FEBS Letters · doi:10.1002/1873-3468.13951 · Cited by 12
Gardner, S. (2021) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2021.100003 · Cited by 12
Genome-wide association study identifies APOE locus influencing plasma p-tau181 levels
Huang, Y., Yang, Y., Wang, H.-F., Shen, X., Tan, L., Yu, J., & Initiative, A. D. N. (2022) · Journal of Human Genetics · doi:10.1038/s10038-022-01026-z · Cited by 12
Neuroinflammation drives APOE genotype-dependent differential expression of neprilysin
Graykowski, D. R., Kasparian, K., Caniglia, J. L., Gritsaeva, Y., & Cudaback, E. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577315 · Cited by 12
Kroll, F., Donnelly, J., Özcan, G. G., Mackay, E., & Rihel, J. (2024) · eLife · doi:10.7554/elife.96839 · Cited by 12
Modeling gene interactions in polygenic prediction via geometric deep learningPreprint
Li, H., Zeng, J., Snyder, M. P., & Zhang, S. (2024) · Genome Research · doi:10.1101/gr.279694.124 · Cited by 12
Bhattarai, P., Yılmaz, E., Cakir, E. Ö., Yüceer, H., Lee, A., Ma, Y., Çelikkaya, H., Coşacak, M. İ., Haage, V. C., Wang, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.24.634732 · Cited by 12
Rare APOE Missense Variants—Can We Overcome APOE ε4 and Alzheimer Disease Risk?
Rabinovici, G. D., & Dubal, D. B. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0854 · Cited by 12
Moosecker, S., Pissioti, A., Leidmaa, E., Harb, M. R., Dioli, C., Gassen, N. C., Yu, S., Gazea, M., Catania, C., Anderzhanova, E., et al. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.10.029 · Cited by 12
Differences in Recycling of Apolipoprotein E3 and E4—LDL Receptor Complexes—A Mechanistic Hypothesis
Kim, M., & Bezprozvanny, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095030 · Cited by 11
Perks, C. M., Barker, R. M., Alhadrami, M., Alkahtani, O., Gill, E., Grishaw, M., Harland, A. J., Henley, P., Li, H., O’Sullivan, E., et al. (2025) · Genes · doi:10.3390/genes16030331 · Cited by 11
Hossain, M. M., Adhikari, J., Dutta, A., Khandaker, A., Islam, S., Rahman, M. M., & Shibly, A. Z. (2025) · PLOS One · doi:10.1371/journal.pone.0331339 · Cited by 11
The Impact of Later-Life Learning on Trajectories of Cognitive Function Among U.S. Older Adults
Wang, N., Xu, H., Dhingra, R., Xian, Y., McConnell, E. S., Wu, B., & Dupre, M. E. (2025) · Innovation in Aging · doi:10.1093/geroni/igaf023 · Cited by 11
Chen, H., Zhang, M., Wei, M., Yu, X., Wang, Y., Yang, J., Li, R., Zhao, W., Wang, X., Zhang, S., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07172-8 · Cited by 11
Pu, Y., Dai, X., Wang, Y., Chen, Y., Wu, C., Zhou, X., Chen, M., Chen, Y., Shuai, X., Jin, R., et al. (2025) · Advanced Materials · doi:10.1002/adma.202418560 · Cited by 11
Chen, H., Dong, X., Wang, Y., Wang, K., Feng, G., Bai, T., Zhang, M., Gan, K., Peng, J.-J., Huang, W., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01548-z · Cited by 11
Lecanemab appropriate use recommendations for clinical practice in the UK
Mummery, C. J., Rasmussen, J., Blackburn, D. J., Coulthard, E. J., Davies, R., Dorsey, R., Fox, N. C., Hosseini, A. A., Ivenso, C., Jones, M. S., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-336597 · Cited by 11
Research Progress of Lipid Metabolism-Mediated Neuroinflammation in Alzheimer’s Disease
Shen, Y., Wang, X., Liu, X., Wang, G., Hou, X., & Zhou, X. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01648-9 · Cited by 12
Suk, K. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115737 · Cited by 11
Talwar, P., Kushwaha, S. S., Rawat, C., Kaur, H., Srivastava, A., Agarwal, R., Chandna, P., Tucci, P., Saso, L., & Kukreti, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.722221 · Cited by 11
Lack of Causal Relationships Between Chronic Hepatitis C Virus Infection and Alzheimer’s Disease
Huang, L., Wang, Y., Tang, Y., He, Y., & Han, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.828827 · Cited by 11
APOE2 Exacerbates TDP‐43 Related Toxicity in the Absence of Alzheimer Pathology
Meneses, A. D., Koga, S., Li, Z., O'Leary, J., Li, F., Chen, K., Murakami, A., Qiao, W., Kurti, A., Heckman, M. G., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26580 · Cited by 11
Self-citationAge-Related Association Between APOE ɛ4 and Cognitive Progression in de novo Parkinson’s Disease
Liu, J.-Y., Ma, L., Wang, J., Cui, X.-J., Sheng, Z.-H., Fu, Y., Li, M., Ou, Y., Yu, J., Tan, L., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220976 · Cited by 11
Role of Lipids in Regulation of Neuroglial Interactions
Galkina, O. V., Vetrovoy, O. V., Krasovskaya, I. E., & Eschenko, N. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923030045 · Cited by 11
A haptoglobin (HP) structural variant alters the effect of APOE alleles on Alzheimer's disease
Bai, H., Naj, A. C., Benchek, P. H., Dumitrescu, L. C., Hohman, T. J., Hamilton‐Nelson, K. L., Kallianpur, A. R., Griswold, A. J., Vardarajan, B. N., Martin, E. R., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13050 · Cited by 11
Ricciardi, N. R., Modarresi, F., Lohse, I., Andrade, N. S., Newman, I. A., Brown, J. M., Borja, C., Marples, B., Wahlestedt, C., & Volmar, C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03373-0 · Cited by 11
Development of a Systems Medicine Approach to Spinal Cord Injury
Guest, J. D., Kelly-Hedrick, M., Williamson, T. L., Park, C., Ali, D. M., Sivaganesan, A., Neal, C. J., Tator, C. H., & Fehlings, M. G. (2023) · Journal of Neurotrauma · doi:10.1089/neu.2023.0024 · Cited by 11
LRP1 is the cell‐surface endocytosis receptor for vaspin in adipocytes
Tindall, C. A., Möhlis, K., Rapöhn, I., Dommel, S., Riedl, V., Schneekönig, M., Höfling, C., Roßner, S., Stichel, J., Beck‐Sickinger, A. G., et al. (2023) · FEBS Journal · doi:10.1111/febs.16991 · Cited by 11
Marques, S. M., Kouba, P., Legrand, A., Sedlář, J., Disson, L., Planas-Iglesias, J., Sanusi, Z. K., Kunka, A., Damborský, J., Pajdla, T., et al. (2024) · JACS Au · doi:10.1021/jacsau.4c00182 · Cited by 11
Protein intake and episodic memory: the moderating role of the apolipoprotein E ε4 status
Keum, M., Lee, B. C., Choe, Y. M., Suh, G., Kim, S. G., Kim, H. S., Hwang, J., Yi, D., & Kim, J. W. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01546-0 · Cited by 11
Min, J.-H., Sarlus, H., & Harris, R. A. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1467333 · Cited by 11
Generation and validation of APOE knockout human iPSC-derived cerebral organoids
Martens, Y. A., Xu, S., Tait, R., Li, G., Zhao, X. C., Lü, W., Liu, C., Kanekiyo, T., Bu, G., & Zhao, J. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100571 · Cited by 11
Self-citationFokuoh, E., Xiao, D., Fang, W., Liu, Y., Lu, Y., & Wang, K. (2021) · Journal of Genetics · doi:10.1007/s12041-021-01309-y · Cited by 11
Pievani, M., Mega, A., Quattrini, G., Guidali, G., Ferrari, C., Cattaneo, A., D’Aprile, I., Mascaro, L., Gasparotti, R., Corbo, D., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210659 · Cited by 11
Mullany, S., Marshall, H. N., Díaz‐Torres, S., Berry, E. C., Schmidt, J. M., Thomson, D., Qassim, A., To, M., Dimasi, D. P., Kuot, A., et al. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100159 · Cited by 11
Diaz, J. R., Martá-Ariza, M., Khodadadi‐Jamayran, A., Heguy, A., Tsirigos, A., Pankiewicz, J. E., Sullivan, P. M., & Sadowski, M. J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.845291 · Cited by 11
Cheng, F., Fransson, L., & Mani, K. (2020) · Glycobiology · doi:10.1093/glycob/cwaa120 · Cited by 11
Yesiltepe, M., Yin, T., Tambini, M., Bao, H., Pan, M., d’Abramo, C., Giliberto, L., Han, X., & D’Adamio, L. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01832-2 · Cited by 10
“APOE4 , the ancestral form of APOE , is has arginine residues at positions 112 and 158 [1] and is present in about 12% of the population.”
BackgroundFu, Q., Pan, G., Yu, Q., Liu, Z., Shen, T., Ma, X., & Jiang, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1456005 · Cited by 10
Implications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders
Zhang, Q., Yim, R., Lee, P., Chin, L., Li, V., & Gill, H. (2024) · Cancers · doi:10.3390/cancers16234118 · Cited by 10
Patil, S. P., Kuehn, B. R., McCullough, C., Bates, D., Hazim, H., Diallo, M., & Francois, N. (2025) · Molecules · doi:10.3390/molecules30040940 · Cited by 10
Lipid mediated formation of antiparallel aggregates in cerebral amyloid angiopathy
de Oliveira, A. P., Baghel, D., Holcombe, B., Chase, W., Ward, T., Wang, S. J., & Ghosh, A. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02911-5 · Cited by 10
de Frutos‐Lucas, J., Cuesta, P., Ramírez‐Toraño, F., Nebreda, A., Cuadrado‐Soto, E., Peral‐Suárez, Á., López‐Sanz, D., Bruña, R., Pedro, S. M.-D., Delgado‐Losada, M. L., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00681-8 · Cited by 10
Li, W., Li, R., Yan, S., Zhao, Z., Shan, Y., Qi, Z., Lu, J., & Initiative, A. D. N. (2022) · European Journal of Neurology · doi:10.1111/ene.15656 · Cited by 10
Mamalaki, E., Charisis, S., Mourtzi, N., Hatzimanolis, A., Ntanasi, E., Kosmidis, M. H., Constantinides, V. C., Παντές, Γ., Kolovou, D., Dardiotis, E., et al. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2023.2187952 · Cited by 10
Shan, L., Li, X., Zheng, X., Wu, J., Ren, H., Liu, W., & Wang, P. (2023) · Molecules · doi:10.3390/molecules28186626 · Cited by 10
Novel Development and Prospects in Pathogenesis, Diagnosis, and Therapy of Alzheimer’s Disease
Teng, Z. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230130 · Cited by 10
Ganesan, K., Rentsch, P., Langdon, A., Milham, L. T., & Vissel, B. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1357405 · Cited by 11
Soldevila‐Domenech, N., Fagundo, A. B., Cuenca‐Royo, A., Forcano, L., Gomis‐González, M., Boronat, A., Pastor, A., Castañer, O., Zomeño, M. D., Goday, A., et al. (2024) · Nutrition Journal · doi:10.1186/s12937-024-00966-w · Cited by 12
McMillan, I. O., Liang, L., Su, G., Song, X., Drago, K., Yang, H., Alvarez, C., Sood, A., Gibson, J. M., Woods, R. J., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107691 · Cited by 11
Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review
Islam, M. R., Rabbi, M. A., Hossain, T., Sultana, S., & Uddin, S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00360 · Cited by 10
Zhu, Y., Benos, P. V., & Chikina, M. D. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae411 · Cited by 10
Inhibiting mtDNA transcript translation alters Alzheimer's disease‐associated biology
Gabrielli, A. P., Novikova, L., Ranjan, A., Wang, X., Ernst, N. J., Abeykoon, D., Roberts, A., Kopp, A., Mansel, C. O., Qiao, L., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14275 · Cited by 10
The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms
Rosal, A. E., Martin, S. L., & Strafella, A. P. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1515374 · Cited by 10
Brain organoids shed light on APOE genotype and Alzheimer disease pathology
Fyfe, I. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-00437-w · Cited by 10
Serum Glycoproteomics and Identification of Potential Mechanisms Underlying Alzheimer’s Disease
Kerdsaeng, N., Roytrakul, S., Chanprasertyothin, S., Charernwat, P., Chansirikarnjana, S., Sritara, P., & Sirivarasai, J. (2021) · Behavioural Neurology · doi:10.1155/2021/1434076 · Cited by 10
Building in vitro models of the brain to understand the role ofAPOEin Alzheimer’s disease
Pinals, R. L., & Tsai, L. (2022) · Life Science Alliance · doi:10.26508/lsa.202201542 · Cited by 10
de Florès, R., Demeilliez-Servouin, S., Kuhn, E., Chauveau, L., Landeau, B., Delcroix, N., Gonneaud, J., Vivien, D., & Chételat, G. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106127 · Cited by 10
Dong, Y., Cao, K., Xiang, J., Qi, X.-L., Xiao, Y., Yu, W., He, Y., Hong, W., & Guan, Z.-Z. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.04.023 · Cited by 10
Wang, F. M., Davis, M. F., & Briggs, F. B. S. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520921073 · Cited by 10
Murakami, R., Watanabe, H., Hashimoto, H., Kashiwagi-Hakozaki, M., Hashimoto, T., Karch, C. M., the Dominantly Inherited Alzheimer Network (DIAN), Iwatsubo, T., & Okano, H. (2024) · The Journal of Neuroscience · doi:10.1523/jneurosci.1709-23.2024 · Cited by 9
Lee, B. C., Choe, Y. M., Suh, G., Choi, I.-G., Lee, J. H., Kim, H. S., Hwang, J., Yi, D., & Kim, J. W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1065117 · Cited by 9
Association of liver fibrosis with cognitive decline in Parkinson’s disease
Zolin, A., Zhang, C., Ooi, H. Y., Sarva, H., Kamel, H., & Parikh, N. S. (2023) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2023.11.019 · Cited by 9
Thyroid Hormone and Alzheimer Disease: Bridging Epidemiology to Mechanism
Escamilla, S., & Salas-Lucia, F. (2024) · Endocrinology · doi:10.1210/endocr/bqae124 · Cited by 9
Wang, B., Chibnik, L. B., Choi, S. H., Blacker, D., DeStefano, A. L., & Lin, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-90277-9 · Cited by 9
Cerebral hypoperfusion, brain structural integrity, and cognitive impairment in older APOE4 carriers
Pappas, I., Lohman, T., Dutt, S., Kapoor, A., Engstrom, A. C., Alitin, J. P. M., Barnes, S. R., Chakhoyan, A., Saca, L., Gaggar, R., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01642-5 · Cited by 9
Ding, J., Sun, B., Gao, Y., Gu, C., Zhang, J., Wang, L., Zheng, J., Xia, B., & Qi, X. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70536 · Cited by 9
Chen, Y., Jiang, B., Zhuang, K., Wang, H., Peng, H., Zhong, B., Xie, W., Chen, K.-W., Zou, T., Wang, Y., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03217-4 · Cited by 9
Wadop, Y. N., Bernal, R., Njamnshi, W. Y., Satizábal, C. L., Beiser, A., Ruiz, A., NJAMNSHI, A. K., Vasan, R. S., Seshadri, S. S., Himali, J. J., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13412-6 · Cited by 10
Impact of APOE on cerebrovascular lipid profile in Alzheimer’s disease
Inoue, Y., Wang, H., Heckman, M. G., Ren, Y., White, L. J., Lü, W., Wang, P., Julia, T. C. W., Koga, S., Alnobani, A., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02949-5 · Cited by 9
Self-citationAPOE4 drives widespread changes to the hepatic proteome and alters metabolic function
Lysaker, C. R., Johnson, C. N., Csikós, V., Franczak, E., Tetlow, A. L., Benson, M. N., Thyfault, J. P., Geiger, P. C., Morris, J. K., & Wilkins, H. (2026) · iScience · doi:10.1016/j.isci.2026.115035 · Cited by 9
Makkapati, M., Ramesha, G. B., Krishna, K. L., Ambika, M. S., Nadig, A. P. R., Pathak, S., & Jalawadi, P. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150226 · Cited by 9
APOE ε4 and exercise interact in a sex‐specific manner to modulate dementia risk factors
Foley, K. E., Diemler, C. A., Hewes, A. A., Garceau, D. T., Sasner, M., & Howell, G. R. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12308 · Cited by 9
Nguyen, T. D., Watanabe, A., Burleigh, S., Ghaffarzadegan, T., Kanklai, J., Prykhodko, O., Hållenius, F. F., & NYMAN, M. E. (2022) · Scientific Reports · doi:10.1038/s41598-022-19502-z · Cited by 9
Chen, X. R., Shao, Y., Sadowski, M. J., & Initiative, O. B. O. T. A. D. N. (2023) · Genes · doi:10.3390/genes14040917 · Cited by 9
Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele
Ji, X., Peng, X., Tang, H., Pan, H., Wang, W. D., Wu, J., Chen, J., & Wei, N. (2023) · Brain Pathology · doi:10.1111/bpa.13208 · Cited by 9
The role of olfactory ensheathing cells in the repair of nerve injury
Liao, J.-X., Zhu, F.-Q., Liu, Y.-Y., Liu, S.-C., Liu, Z.-X., & Zhang, W. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176346 · Cited by 9
Wang, N., Parsons, T. M., Ren, Y., Pan, Y., Kurti, A., Starling, S. C., Muolokwu, C. E., Singh, J., & Kanekiyo, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39607 · Cited by 9
Genome‐wide association analysis identifies APOE as a mitophagy modifier in Lewy body disease
Hou, X., Heckman, M. G., Fiesel, F. C., Koga, S., Soto‐Beasley, A. I., Watzlawik, J. O., Zhao, J., Valentino, R. R., Johnson, P. W., White, L. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70198 · Cited by 9
Self-citationLozupone, M., Dibello, V., Resta, E., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Mollica, A., Berardino, G., et al. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2500752 · Cited by 9
Hua, W., Hou, J., Jiang, T., Su, B., Fu, J., Sun, R., Chang, B., Xia, W., Wu, H., Zhang, T., et al. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.560947 · Cited by 9
Metadata
- Authors
- Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G.
- Affiliations
- Mayo Clinic in Florida (US)
- Corresponding author
- Bu, Guojun
- Venue
- Nature Reviews Neurology
- Published
- 2019-07-31
- Volume
- 15
- Issue
- 9
- Pages
- 501-518
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7055192
- OpenAlex
- W2965401191
- Cited by
- 1,425
- References
- 318
- Citations by year
- 2026: 191 · 2025: 259 · 2024: 233 · 2023: 242 · 2022: 200 · 2021: 172 · 2020: 124 · 2019: 4
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (RF1AG051504, R01AG027924, R37AG027924, RF1AG057181, RF1AG046205, R01AG035355)
- National Institute of Neurological Disorders and Stroke (P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, APOE polymorphism, amyloid-beta, tau pathology, neurodegeneration, microglial activation, lipid transport, synaptic plasticity, glucose metabolism, cerebrovascular function, precision medicine
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Brain, Humans, Polymorphism, Genetic, Amyloid beta-Peptides, Genetic Predisposition to Disease, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
